Disgraced CEO Martin Shkreli faces new charges in pharmaceutical fraud case - Action News
Home WebMail Thursday, November 14, 2024, 12:02 PM | Calgary | 7.1°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
World

Disgraced CEO Martin Shkreli faces new charges in pharmaceutical fraud case

Federal prosecutors in New York have filed additional criminal charges against a pharmaceutical executive who separately was heavily criticized for raising the price of a lifesaving malaria medication.

Notorious executive allegedly schemed to defraud potential investors of his former company

In this Feb. 3 photo, former Turing Pharmaceuticals CEO Martin Shkreli leaves court in New York. A new indictment filed Friday, June 3, 2016, in Brooklyn says Shkreli and his former attorney Evan Greebel schemed to defrauded potential investors of his former drug company Retrophin Inc. (Seth Wenig/Associated Press)

Federal prosecutors in New York have filed additional criminal charges against a pharmaceutical executive who separately was heavily criticized for raising the price of a lifesaving malaria medication.

A new indictment filed Friday in Brooklyn says Martin Shkreliand his former attorney Evan Greebel schemed to defrauded potential investors of his former drug company Retrophin Inc., based in San Diego. They say the two allocated company stock to seven employees to conceal Shkreli's ownership of it.

Shkreli previously pleaded not guilty to charges he lost investors' money through bad trades and looted the pharmaceutical company to pay them back.

Shkreli already was reviled because another drug company he owned raised the price of Daraprim by 5,000 per cent.

Shkreli's attorney says the allegations won't change the "flawed theory" of the case. Greebel's lawyer has no comment.